Clinical Trial Update: Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS [Phase 3]

View source ↗

Summary

Phase 3 randomized, double-blind trial evaluating cenobamate as adjunctive therapy for partial/focal seizures has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Seizure
• Partial Seizure

Drugs mentioned

• Cenobamate (cenobamate)

Snippet

Sponsor: SK Life Science, Inc. | Conditions: Partial Seizure, Focal Seizure | Phase 3 | Status: COMPLETED